news
Breast cancer cells invade by a physical mechanism
Findings from using a 3D hydrogel to study how cancer cells physically tear the basement membrane offers promise for targeted treatment.
List view / Grid view
Therapeutics
news
Improving ovarian cancer outcomes with artificial intelligence
Researchers have developed an AI based model that is 80 percent accurate in predicting the therapy outcome of high-grade ovarian cancer.
article
Understanding intracellular processes improves LYTACs therapy
New pathway involved in cellular protein degradation could develop LYTACs therapy and find new treatments for lysosome shortage disorders.
news
Microcapsule-loading exosomes to treat vitreoretinal diseases
Scientists have developed ExoCaps, self-healing microcapsules that are more feasible than other cell-based technologies.
news
Newly discovered mechanism behind cognitive decline in aging
US researchers say new mechanism could lead to new drugs and therapies to treat normal cognitive decline in aging.
news
Extracellular vesicles could slow spread of fibrosis
US researchers studied the extracellular vesicles of fibrosis and find potential avenue for new treatments and therapeutics.
webinar
Functional assays for the development of agonistic antibodies
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
article
Rare autoantibody diseases: an innovative targeted pathway
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
article
Antibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
article
T cells’ vital role in boosting immune responses
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
whitepaper
Application note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
whitepaper
Product hub: Enhancing drug discovery and development with cutting-edge microplate readers
Dr Marina Junqueira explores the main research interest of a lab focusing on opioids, cannabinoids, terpenoids and 5HT receptor agonists with the aim to understand the molecular-level signaling of drugs and how polymorphisms can affect this process.
video
Video: Four integrated technologies for biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.
article
RNA processing in health and disease: challenges and opportunities of the field
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential…
news
New method of designing drugs without side effects
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
